AzTrials
AzTrials

Compliance, PatientCOCOONNCT06017063

Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields

A study testing Psychological intervention in people with Compliance, Patient and Glioblastoma, run by University Hospital Tuebingen.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Psychological intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
275 participants
Where
No sites listed yet
Study dates
Oct 2023to Sep 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Ability to understand and give an informed consent, capacity to consent
  • Given informed consent
  • ≥ 18 years of age
  • Patients with newly diagnosed glioblastoma
  • Patients with IDH-mutant Astrocytoma, CNS WHO-Grade 4, newly diagnosed (by biopsy or incomplete tumor resection)
  • Patients eligible for radiochemotherapy with temozolomide and 60 Gy
Show all 10Show fewer
  • Patients before radiochemotherapy phase or within the first 2 weeks
  • Prescription of TTFields according clinical routine (including but not exclusive to)
  • Access to a computer and internet
  • Absence of medical reasons precluding participation in a supportive intervention

Who cannot join

  • Ability to understand and give an informed consent, capacity to consent
  • Given informed consent
  • ≥ 18 years of age
  • Being a family caregiver of a patient with newly diagnosed glioblastoma
  • Access to a computer and internet
  • Absence of medical reasons precluding participation in a supportive intervention

Trial locations and contacts

No sites are listed yet.

About this study

The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention in a multi-center, randomized controlled trial.

Read the detailed description

Patients diagnosed with a glioblastoma and their family caregivers are mainly impaired by the poor prognosis and the high symptom burden. Caregivers report impaired health-related quality of life (HRQOL) and high distress. They even may experience significantly higher levels of anxiety and depression than patients themselves . Furthermore, Boele et al. showed that the overall survival in glioblastoma patients is associated with family caregivers' mastery.

In newly diagnosed glioblastoma, the EF-14 RCT demonstrated significantly prolonged survival in patients treated with TTFields compared to controls, with a median overall survival (OS) of 20.9 vs 16.0 months.

Several studies showed an important association of the daily compliance rate with OS and progression-free survival (PFS). Family caregivers' support might be associated to the patients' compliance and adequate support is required. However, so far rare supportive programs for patients and their caregivers have been established. It has been shown that delivery of supportive care via telehealth is feasible, however studies examining the effectiveness, adoption and maintenance of telehealth interventions in glioblastoma patients and family caregivers are still lacking. The aim is to improve patients' compliance to TTFields therapy by a psychological video intervention.

It is a multi-center, randomized controlled trial.

Main inclusion criteria are:

  • Diagnosis of a GBM/being a GBM patient's caregiver
  • Patients eligible for radiochemotherapy with TMZ and 60Gy
  • Tumorboard recommendation for TTFields therapy
  • Access to a computer and internet
  • Absence of medical reasons precluding participation in a supportive intervention

The experimental intervention is:

Delivery of supportive care via telehealth intervention (including a brief psychological intervention and information/educational support regarding the disease, therapy and self-help options) in family caregivers and patients

The intervention encompasses six interventions (video call) for patients and caregivers.

The six sessions will be conducted by the psychologists of the coordinating center to allow homogeneous and sound implementation of the BPI. All psychologists are certified psychooncologists.

The first part of the sessions is scheduled immediately after start of radiochemotherapy (+ 2 weeks) in order to guide patients and caregivers in this important phase after first diagnose.

  • First session/week 1 (+ 2 weeks) after start of radiochemotherapy: Engage and motivate patients and caregivers to participate and to develop open communication (60-90min), followed by a follow up phone call a few days later.
  • Second session/week 2 (+ 2 weeks) after start of radiochemotherapy: Review of the last session and follow-up phone. Education on the techniques for optimistic attitude (including positive self-talk, positive thinking, and speaking positive). Discussion about necessity of setting achievable short-term goals in treatment process. Homework: "Write at least 3 achievable short-term goals" (45 min), followed by a follow up phone call a few days later.

The second part of the sessions is scheduled after completion of radiochemotherapy phase (+ 2 weeks) with focus in the adjuvant temozolomide therapy and TTFields therapy.

  • Third session/week 7 (+ 2 weeks) after completed radiochemotherapy: Review of the last session, discussion over the phone, and homework. Providing information or advice about treatment, the TTFields therapy and medication.
  • Responding to hopelessness (focusing on positive details of the clinical course, the progress which patients made since surgery, but also sharing fears, and negative thoughts). Sharing community resources (websites, hospitals, and counseling centers).
  • Importance of TTFields therapy and association of daily compliance rate with prognosis, FAQ list, recommendations and practical aspects
  • Homework: "Provide a list of supportive resources in your community" "Provide a list of questions to the health care professionals" (45-60min), followed by a follow up phone call a few days later.
  • Fourth session/week 8 (+ 2 weeks) after completed radiochemotherapy:
  • Education on the techniques for stress management (including physical activity, social contact/relationship, spending time in activity and nature (60-90 minutes) and healthy lifestyle behaviors.
  • Questions regarding TTFields and chemotherapy
  • Homework: "List the useful strategies to manage your stress during the treatment process of your partner", "Apply stress management techniques". (45-60min), followed by a follow up phone call a few days later.
  • Fifth session/week 9 (+ 2 weeks) after completed radiochemotherapy:
  • First assessment after start of TTFields therapy, evaluation of practical questions and well-being
  • Education of self-care strategies (including eating well-balanced meals, permission to feel bad-schedule it in your day, permission to feel good, put off major life decisions (if it is possible), take breaks from periods of isolation, exercise - even a little bit, and let yourself cry (45-60 min).
  • Sixth session/week 10 (+ 2 weeks) after completed radiochemotherapy: Feedback regarding the sessions before and planning of implementation of the learned strategies for the upcoming months. Homework: "List the strategies personally useful and what personally motivates you, learned in the last weeks"

The control condition is: Standard of care with standard access to psychosocial support in certified Neuro-Oncological Centers

Primary Outcome:

Compliance to TTFields compared in intervention and control group

Secondary Outcomes:

  • Patients' health-related quality of Life (HRQoL), symptom burden, self-efficacy, anxiety, depression and its association to the intervention.
  • Patient- and family caregiver-reported acceptance of intervention, patients´ acceptance of TTFields
  • Adverse event of special interest: Skin irritation
  • Patients' and family caregivers emotional and physical well-being,
  • Correlation between endpoints to investigate dependencies of underlying concepts.
  • Analysis of health utilization measures.

Optional Outcomes:

On a voluntary basis the following biosamples will be acquired for assessment of stress level and immunogenic response

  • hair probes
  • blood
Being tested
Psychological intervention
Keywords
psychosocial support
Medical subject headings
Patient Compliance, Glioblastoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Psychological interventionOther

    The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.

Study groups in NCT06017063
Study groupRoleWhat they receive
Intervention armExperimentalPatients and caregivers will participate in support program encompassing six video interventions with the BPI. Both participate in the intervention at the same time and together. The intervention starts within two weeks after start of the radiochemotherapy phase, see also figure 2. Patients and caregivers will receive an invitation link to the Vidyo sessions and can log in together to participate in the sessions.
Receives: Other: Psychological intervention
Control armNo interventionPatients and caregivers randomized to the control group, they will not receive the 6-week intervention by the psycho-oncologist. However, they are still entitled to guideline-based psycho-oncology counseling according to the guideline and local standard if they wish. Subsequently, they will be supported regarding coping with the disease, how to improve their mood, or which strategies are available in dealing with the disease. This conversation will last 30-60 minutes.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EFFICACY of intervention

    Compliance to TTFields compared in intervention and control group.Compliance will be measured by the duration of the TTFields application in each patient

    Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)

Secondary outcomes (3)
  1. TOLERABILITY of psychooncological intervention

    Patient- and caregiver-reported acceptance of intervention as measured by number of patient and cargiver dyads who completed the 6th session of the psychooncological intervention

    Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)

  2. Safety of TTFields

    Adverse event of special interest: Skin irritation in patients under TTFields therapy

    Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)

  3. Incidence of burdened caregivers

    Caregiver emotional and physical well-being, patient emotional and physical well-being

    Measured: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2023
  2. Study startOct 2023 (estimated)
  3. Primary completionApr 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
randomized controlled trial
Masking
None (open label)
Enrolment
275 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06017063
Sponsor's protocol ID
345/2023BO1
Acronym
COCOON
Status last verified
Jul 2023
First submitted
12 Jul 2023
Last updated
30 Aug 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Psychological intervention in people with Compliance, Patient and Glioblastoma, run by University Hospital Tuebingen.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 30 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mirjam Renovanz, MD (0049 7071 29 61903, mirjam.renovanz@med.uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EFFICACY of intervention (time frame: 9 months, last visit after completed 6 cycle of adjuvant Temozolomide (each cycle is 28 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
COCOON Clinical Trial NCT06017063 | AzTrials